Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -1.64B | -959.00M | -453.00M | -479.00M | -560.00M |
Total Depreciation and Amortization | 1.06B | 1.06B | 1.08B | 1.12B | 1.15B |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 2.26B | 1.66B | 983.00M | 967.00M | 847.00M |
Change in Net Operating Assets | -435.00M | 102.00M | -442.00M | -220.00M | -72.00M |
Cash from Operations | 1.25B | 1.86B | 1.17B | 1.39B | 1.37B |
Capital Expenditure | -498.00M | -488.00M | -489.00M | -511.00M | -526.00M |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -15.00M | -15.00M | -15.00M | -15.00M | -- |
Divestitures | 43.00M | 39.00M | 11.00M | 66.00M | 68.00M |
Other Investing Activities | 1.26B | 1.36B | 1.30B | 1.39B | 1.43B |
Cash from Investing | 792.00M | 891.00M | 807.00M | 931.00M | 968.00M |
Total Debt Issued | -- | 0.00 | 700.00M | 700.00M | 3.15B |
Total Debt Repaid | -1.64B | -1.46B | -2.66B | -1.70B | -4.85B |
Issuance of Common Stock | -- | -- | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -150.00M | -237.00M | -313.00M | -358.00M | -212.00M |
Cash from Financing | -1.79B | -1.69B | -2.27B | -1.36B | -1.91B |
Foreign Exchange rate Adjustments | -174.00M | 15.00M | -118.00M | -146.00M | -30.00M |
Miscellaneous Cash Flow Adjustments | -1.00M | 0.00 | 0.00 | -1.00M | -- |
Net Change in Cash | 73.00M | 1.07B | -412.00M | 815.00M | 393.00M |